HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: For example, the lung tumour cell subcluster LUAD_P04T was specifically matched to vorinostat, a histone deacetylase (HDAC) inhibitor that can block cancer cell proliferation both in vitro and vivo, and has been approved by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma [81].